Overview
The Institute of Hematology & Blood Diseases Hospital (IHCAMS), located in Tianjin, is China’s leading national center for hematology and one of the country’s most prestigious institutions for the diagnosis, treatment, and research of blood disorders. Established in 1957, the hospital serves as the National Clinical Research Center for Blood Diseases and is widely recognized for its expertise in leukemia, lymphoma, multiple myeloma, aplastic anemia, hemophilia, and stem cell transplantation.
IHCAMS has played a pioneering role in the development of advanced cellular therapies in China, including CAR-T cell therapy, stem cell transplantation, and innovative immunotherapies. The hospital is actively involved in clinical research and international collaborations, providing patients with access to cutting-edge treatments and clinical trials.
The institution brings together a multidisciplinary team of renowned hematologists, transplant specialists, laboratory scientists, and researchers. Its comprehensive approach combines precise diagnosis, personalized treatment planning, advanced laboratory testing, and long-term follow-up care.
For international patients seeking specialized treatment for blood cancers and hematologic diseases, IHCAMS offers access to world-class expertise, advanced medical technologies, and some of China’s most experienced teams in cellular and gene-based therapies.
Frequently Asked Questions
1. What is IHCAMS known for?
IHCAMS is China’s leading specialty hospital for blood diseases and hematologic cancers. The hospital is recognized for its expertise in leukemia, lymphoma, multiple myeloma, aplastic anemia, hemophilia, stem cell transplantation, and cellular therapies.
2. Does IHCAMS offer CAR-T cell therapy?
Yes. IHCAMS has extensive experience in CAR-T cell therapy and participates in clinical research and treatment programs for patients with relapsed or refractory blood cancers, including leukemia, lymphoma, and multiple myeloma.
3. Can international patients receive treatment at IHCAMS?
Yes. International patients can access consultations, diagnostic services, treatment planning, stem cell transplantation, CAR-T therapy, and other advanced hematology treatments through international patient support services.
4. What types of blood disorders are treated at IHCAMS?
The hospital treats a wide range of conditions, including acute and chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), aplastic anemia, hemophilia, thalassemia, and other rare blood diseases.
5. Why do patients choose IHCAMS for treatment?
Patients choose IHCAMS because of its nationally recognized specialists, advanced treatment technologies, strong research capabilities, extensive experience in stem cell transplantation and CAR-T therapy, and access to innovative clinical trials that may not be available elsewhere.
